SCHEMBL1102546

SCHEMBL1102546

c1ccc2c(c1)Oc1ccccc1N2c1c2ccccc2c(N2c3ccccc3Oc3ccccc32)c2cnccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.39
MAOB P27338 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ACHE P22303 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
IKBKB O14920 1/20 0.39
AURKA O14965 1/20 0.39
CHUK O15111 1/20 0.39
PIM1 P11309 1/20 0.39
TOP1 P11387 1/20 0.39
GABRA1 P14867 1/20 0.39
IDO1 P14902 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102891 0.90 ALOX5 (0.36) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102713 0.86 TNF (0.39) SMN1; SMN2KDM4EALDH1A1HPGDIDO1
SCHEMBL1102850 0.84 CYP11B1 (0.38) SMN1; SMN2TDO2MAPTNPSR1NPC1
SCHEMBL1102506 0.79 ACHE (0.45) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102505 0.79 HPGD (0.38) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102734 0.79 P2RX4 (0.39) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102517 0.79 ADRA2A (0.38) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102544 0.79 STAT3 (0.38) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL1102553 0.78 LMNA (0.37) MAOAMAOBSMN1; SMN2KDM4EACHE
SCHEMBL17954913 0.76 KDM4E (0.45) SMN1; SMN2KDM4EALDH1A1IDO1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAOA 1588/4885MAOB 1209/4885SMN1; SMN2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.